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Edited by Jesus AvilaAbstract b-Synuclein exhibits high sequence homology and
structural similarity with a-synuclein, a protein implicated in the
pathogenesis of Parkinson’s disease. We investigated the chap-
erone function of b-synuclein and its anti-ﬁbrillar activity in
comparison with a-synuclein. b-Synuclein suppressed the heat-
induced aggregation of aldolase, alcohol dehydrogenase, and
citrate synthase, and its anti-aggregative activity was remark-
ably higher than that of a-synuclein. Heat-induced inactivation
of citrate synthase was signiﬁcantly protected by b-synuclein.
Moreover, b-synuclein inhibited the amyloid formation of both
Ab1–40 and a-synuclein. It is, therefore, suggested that b-
synuclein can prevent abnormal protein aggregations more
eﬀectively than a-synuclein by acting as a molecular chaperone.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Synuclein was ﬁrst isolated in Torpedo californica [1] and
found to be a neuron-speciﬁc protein in rat [29]. The human
homolog of the protein was named a-synuclein and a related
protein known as b-synuclein was reported to be another hu-
man homolog of bovine phosphoneuroprotein 14 [2]. c-Syn-
uclein is the third member of the synuclein family and known
as breast cancer-speciﬁc gene 1 [3]. These three synucleins are
intrinsically unstructured in their native states and share a high
degree of sequence identity especially within their N-terminal
regions.
Among the synuclein family, much more research eﬀorts
have been focused on a-synuclein because of its major presence
in Lewy bodies, which are abnormal protein inclusions
associated with Parkinson’s disease (PD) and several other
neurodegenerative disorders [27]. Missense mutations of a-
synuclein were discovered in a few pedigrees of familial PD
[4–7], and PD-like phenotypes were developed in the trans-
genic mice and ﬂies with a-synuclein overexpression [8,9]. The
fact that a-synuclein bound to synthetic membranes and brain
vesicles along with its presynaptic localization [10,11] led to the
suggestion of its physiological function in synaptic plasticity.
a-Synuclein was implicated in the regulation of dopamine* Corresponding author. Fax: +82-54-279-8066.
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resting pools of presynaptic vesicles [13,14]. a-Synuclein also
exhibited chaperone activity, which protects proteins from
being aggregated thermally or chemically in vitro [15,16].
Unlike a-synuclein whose structural and functional prop-
erties were extensively investigated, relatively minor attention
was paid to b-synuclein regarding its physiological roles and
any implications in the pathogenesis. Both a- and b-synu-
cleins have been abundantly expressed and localized in the
presynaptic nerve terminal of human brain [2]. While mRNA
level of b-synuclein is high in a normal brain, the level has
been decreased in the brain of Lewy body disease patients,
especially in the area of substantia nigra. a-Synuclein level,
on the other hand, was found to be increased signiﬁcantly in
the substantia nigra, where selective loss of the dopaminergic
neurons occurred up to 70–80% in PD [17]. Since b-synuclein
inhibited the accumulation of asynuclein in transgenic mice
and cell lines, and this inhibitory eﬀect was further demon-
strated in in vitro ﬁbrillization of a-synuclein, it was hy-
pothesized that the protein might be a negative regulator of
the amyloid formation of a-synuclein [18,19]. b-Synuclein has
been also known to display antiapoptotic function [20] and to
protect neurons from neurotoxin by regulating protein kinase
B/Akt activity [31].
Despite putative physiological roles of b-synuclein as men-
tioned above, the exact function of b-synuclein is still elusive.
In this report, we propose that b-synuclein is a molecular
chaperone which exhibits more eﬀective chaperone activity
than a-synuclein against heat-induced protein aggregations.
Moreover, b-synuclein inhibits the in vitro amyloid formation
of both amyloid b/A4 protein (Ab1–40) and a-synuclein. Our
ﬁndings suggest that b-synuclein be one of the eﬀective anti-
aggregative agents inside the cell. Therefore, b-synuclein ex-
hibited a potential for therapeutic or prophylactic treatment of
neurodegenerative diseases involved in misfolding and sub-
sequent aggregations of proteins.2. Materials and methods
2.1. Puriﬁcation of a- and b-synucleins
Both a- and b-synucleins were produced and puriﬁed according to
the procedures as described previously [21] with minor modiﬁcations.
Brieﬂy, heat-treated cell lysate containing a-synuclein was loaded onto
a DEAE Sephacel anion-exchange (Pharmacia Biotech, Sweden) col-
umn, which had been equilibrated with an equilibrium buﬀer con-
taining 0.1 M NaCl and 20 mM Tris–Cl, pH 7.5, and eluted with an
elution buﬀer containing 0.2 M NaCl and 20 mM Tris–Cl, pH 7.5.ation of European Biochemical Societies.
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exclusion chromatography was performed with an elution buﬀer of 20
mM MES, pH 6.5, and the eluate was applied onto a Mono S HR 5/5
column (Pharmacia Biotech, Sweden) equilibrated with 20 mM MES,
pH 6.5. The protein was eluted with a linear gradient of 0–0.5 M NaCl.
The collected fractions were concentrated and desalted using a Fast
desalting column (Pharmacia Biotech, Sweden). b-Synuclein was iso-
lated by ion-exchange chromatography using DEAE and Mono Q
anion-exchangers as described previously [30]. The puriﬁed synucleins
were dialyzed against 20 mM MES, pH 6.5, and stored in aliquots at
)20 C.
2.2. Chaperone activity of synucleins against heat-induced protein
aggregation
Prevention of heat-induced protein aggregation by the synucleins
was investigated according to the methods described previously
[15,16]. The protein aggregation was induced at 60 C in 25 mM
sodium phosphate, pH 7.4. Various amounts of synucleins were ad-
ded in the reaction mixture containing 2.5 lM aldolase or alcohol
dehydrogenase (ADH) (Sigma, USA). Light scattering at 405 nm was
measured during the incubation by use of a spectrophotometer (UV-
2501 PC, Shimadzu, Japan) with a built-in water circulator for
constant temperature.
The aggregation of ADH was induced by heat treatment in the
presence or absence of b-synuclein. 2.5 lM ADH was incubated with
14.1 lM b-synuclein at 60 C for 10 min and the reaction mixtures
were then centrifuged at 15 000 g for 30 min. The supernatant was
removed completely and a sample buﬀer containing 0.125 M Tris–Cl,
pH 6.8, 4% SDS, 20% glycerol, 0.2 M DTT, and 0.02% bromophenol
blue was added to the pellets before heating at 100 C. Inhibition of
ADH precipitation by b-synuclein was assessed by 15% SDS–PAGE.
2.3. Eﬀect of synucleins on the aggregation and inactivation of citrate
synthase
The porcine heart citrate synthase (CS) (Sigma, USA) dissolved in a
buﬀer containing 2.2 M (NH4)2SO4, pH 7.0, 60 mM phosphate, and
0.5 mM citrate was dialyzed against a solution containing 50 mM Tris–
Cl, pH 8.0, and 2 mM EDTA. The dialyzed solution was centrifuged at
15 000 g for 10 min to remove any precipitate, and then was divided
into aliquots and stored at )20 C. To determine synuclein eﬀects on
the protein aggregation and inactivation of the enzyme, 0.5 lMCS was
incubated in 40 mM HEPES, pH 7.5, at 43 C in the absence or
presence of indicated concentrations of either a- or b-synuclein. The
thermal aggregation of CS was assessed by monitoring the change of
light scattering using a spectroﬂuorophotometer (RF-5301 PC, Shi-
madzu, Japan) with both excitation and emission wavelengths at 360
nm. To determine the CS activity during the thermal inactivation,
enzymatic assays were performed as described previously [22] with the
minor modiﬁcations in which 20 ll aliquot was taken from 0.5 lM CS
mixture during the thermal inactivation process and added to the assay
mixture containing 0.1 mM oxaloacetic acid, 0.15 mM acetyl-CoA,
and 0.1 mM 5,50-dithio-bis (2-nitrobenzoic acid) in a buﬀer containing
50 mM Tris–Cl, pH 8.0, and 2 mM EDTA. The assay was carried out
at 25 C and the CS activity was determined by measuring the
absorbance of the assay mixture at 412 nm utilizing 5,50-dithio-bis
(2-nitrobenzoic acid) as described previously [22].
2.4. b-Synuclein-mediated inhibition of the ﬁbrillizations of Ab1–40 and
a-synuclein
Ab1–40 (Sigma, USA) was initially dissolved in 100% dimethyl sulf-
oxide, and then diluted in the buﬀer containing 10 mM phosphate, pH
7.4, and 150 mM NaCl. 50 lM Ab1–40 was incubated in the absence or
presence of equimolar concentration of either a- or b-synuclein at 37
C. The concentration of dimethyl sulfoxide in the reaction mixture
was maintained at less than 5% in order to exclude any eﬀect of the
organic solvent. To determine the eﬀect of b-synuclein on the a-syn-
uclein ﬁbrillization, 100 lM a-synuclein was incubated with equimolar
b-synuclein at 37 C. At each designated time point, an aliquot (5 ll) of
the solution from each reaction mixture was taken for the thioﬂavin-T
binding ﬂuorescence assay as described previously [23]. Fluorescence
intensities were measured using a spectroﬂuorophotometer at 25 C
with a 1 cm pathlength quartz cell. The excitation wavelength was 440
nm and the emission was monitored between 400 and 500 nm. The
relative ﬂuorescence at 485 nm was used to quantify the amount of
ﬁbrillar aggregates.3. Results and discussion
a-Synuclein has been suggested to have a molecular chap-
erone activity as a potential physiological function [15,16,24].
Since the amino acid sequence of b-synuclein is almost iden-
tical to that of a-synuclein in the N-terminal region while ex-
hibiting a distinct feature in the C-terminus, which has been
suggested to be responsible for the chaperone activity of a-
synuclein, we examined the capability of b-synuclein to prevent
heat-induced protein aggregations of aldolase and ADH. Like
a-synuclein, b-synuclein prevented the aggregation of dena-
tured aldolase and ADH during the incubation at 60 C
(Fig. 1). The presence of 14.1 lM b-synuclein in the mixture
containing 2.5 lM aldolase resulted in 46% reduction in the
protein aggregation after 500 s of the incubation, and the in-
hibitory eﬀect appeared to be dose-dependent as it was de-
creased up to 80% in the presence of 28.2 lM b-synuclein
(Fig. 1A). The chaperone activity of b-synuclein was even
more dramatic when examined using ADH as a substrate.
When 2.5 lM ADH was incubated with 14.1 lM b-synuclein,
almost 90% of the aggregation of ADH was prevented after
500 s of the incubation (Fig. 1B). Thus, b-synuclein exhibited
diﬀerent eﬃciency of chaperone activity depending on the
kinds of the substrate. On the other hand, when the con-
centration of a-synuclein was adjusted to 13.9 lM or 27.8 lM
in the reaction mixture containing 2.5 lM ADH, the heat-in-
duced aggregation of the protein was suppressed by only 26%
and 32%, respectively (data not shown). Therefore, b-synuclein
exhibited higher chaperone activity than a-synuclein. The
chaperone activity of b-synuclein was further conﬁrmed by
analyzing the amount of precipitated ADH after the incuba-
tion at 60 C for 10 min by SDS–PAGE (Fig. 1C). When ADH
was incubated without any additional protein or with a non-
speciﬁc protein like BSA, a signiﬁcant amount of ADH was
found in the precipitate after centrifugation for 30 min.
However, the amount of precipitated ADH was remarkably
decreased in the presence of b-synuclein in agreement with the
result from the light scattering measurement.
CS is also a very sensitive substrate for examining chaperone
activity. The enzyme loses its activity and forms protein ag-
gregates within minutes during the incubation at 43 C. 0.5 lM
CS was incubated at 43 C and the changes of light scattering
at 360 nm were monitored during the incubation periods
(Fig. 2A). Light scattering was increased after 4 min of the lag
period. The aggregation of CS was clearly suppressed by b-
synuclein, while a-synuclein did not aﬀect the aggregation at
all. To achieve 50% suppression of the CS aggregation, the
equimolar concentration of b-synuclein was suﬃcient. Addi-
tion of 2-fold molar excess of b-synuclein suppressed 70% of
the CS aggregation. Thus, this inhibitory eﬀect of b-synuclein
was dose-dependent (Fig. 2A). In concert with the overall
decrease in the CS aggregation, the lag phase in the CS ag-
gregation kinetics was extended in a dose-dependent manner as
well.
Since CS readily loses its activity during the incubation at
elevated temperature, the eﬀect of synucleins on the heat-in-
duced inactivation of CS was investigated. As shown in
Fig. 2B, the enzyme activity of CS decreased rapidly. After
incubation for 6 min at 43 C, less than 20% of the enzyme
activity was retained. However, the presence of the equimolar
b-synuclein dramatically slowed down the inactivation rate of
CS; over 60% of CS activity still remained after 6 min of heat
Fig. 2. Inﬂuence of a- or b-synuclein on the heat-induced citrate syn-
thase (CS) aggregation and inactivation. (A) 0.5 lM CS was incubated
at 43 C in the absence (d) or presence of 0.5 lM a-synuclein (,), and
0.5 lM (s) and 1 lM (.) b-synuclein, respectively. (B) During the
heat-induced CS aggregation at 43 C, 20 ll of the reaction mixture at
each time point was subjected to CS activity assay at room tempera-
ture. The remaining activities of CS at each time point were plotted
in the absence (d) or presence of equimolar a-synuclein (m) and b-
synuclein (n).
Fig. 1. Chaperone activity of b-synuclein against the heat-induced
protein aggregation of aldolase and alcohol dehydrogenase (ADH).
(A) 2.5 lM aldolase was incubated at 60 C in the absence (—) or
presence of either 14.1 lM (  ) or 28.2 lM (– –) b-synuclein. (B) 2.5
lM ADH was incubated at 60 C in the absence (—) or presence of
either 7 lM (  ) or 14.1 lM (– –) b-synuclein. The aggregation ki-
netics was monitored by measuring light scattering at 360 nm. The line
(–  ) represents the aggregation of b-synuclein by itself. (C) 2.5 lM
ADH was incubated in the absence or presence of 14.1 lM b-synuclein
or BSA for 10 min at 60 C. After immediate centrifugation, the
precipitation of ADH was analyzed by 15% SDS–PAGE. The ADH
standard and the unheated ADH in the precipitate were shown as
controls.
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the protein aggregation and the thermal inactivation of the
enzyme activity. The rate constants for the inactivation of the
CS activity were estimated to be 2.11 105 or 0.8 105 s1
in the absence or presence of b-synuclein, respectively
(Fig. 2B). The rate constant was decreased by 2.54-fold in thepresence of b-synuclein. However, a-synuclein contributed to
only marginal reduction in the inactivation process of the CS
activity, since the CS activity retained after 6 min incubation
with a-synuclein was similar to that in the absence of addi-
tional synucleins (Fig. 2B).
Based on the anti-aggregative property of b-synulein, we
investigated whether b-synuclein could exhibit an anti-ﬁbrillar
activity to suppress the ﬁbril formation of both amyloid b/A4
protein (Ab) and a-synuclein, which are known to play sig-
niﬁcant roles in Alzheimer’s disease (AD) and PD pathoge-
neses, respectively. The Ab with 39–43 amino acids are
peptides derived from the amyloid precursor protein (APP).
These peptides are the major constituent of extracellular
amyloid plaques in the brain of AD patients and also have
capability to form ﬁbrils in certain conditions in vitro [27]. b-
Synuclein was found to suppress the ﬁbrillization of Ab1–40
signiﬁcantly as shown in Fig. 3A. By incubating with an
equimolar b-synuclein at 37 C, the aggregate formation of
Ab1–40 was signiﬁcantly suppressed during the incubation
Fig. 3. Inhibitory eﬀect of b-synuclein on the amyloid formation of
amyloid b/A4 protein (Ab1–40) and a-synuclein. (A) 50 lM Ab1–40 was
incubated at 37 C in the absence (d) or presence of either 50 lM a-
synuclein (,) or b-synuclein (j). As controls, the extent of the ag-
gregation of a-synuclein () and b-synuclein (r) is also presented
during the same incubation period. (B) 100 lM a-synuclein was in-
cubated with equimolar b-synuclein (.). Aggregation of a-synuclein
(d) or b-synuclein (j) is shown as controls. The extent of aggregation
was determined by the thioﬂavin-T binding ﬂuorescence assay [23].
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thioﬂavin T. In contrast, a-synuclein had no such inhibitory
eﬀect. The suppressive activity of b-synuclein continued during
prolonged incubation over 3 weeks (data not shown). In
agreement with previous reports [18,19], the ﬁbrillization of a-
synuclein was also inhibited in the presence of equimolar
amount of b-synuclein (Fig. 3B). b-Synuclein itself did not
inﬂuence the ﬂuorescence intensity caused by the binding of
the amyloid to thioﬂavin-T. Although the mechanism of b-Fig. 4. Alignment of amino acid sequence between various Hsp 90 proteins
program (http://prodes.toulouse.inra.fr/multalin/multalin.html). Conserved asynuclein action on the Ab1–40 aggregation is unknown and
remains to be further investigated, b-synuclein was found to
not only act as an inhibitor of a-synuclein ﬁbrillization but
also exhibit the similar anti-ﬁbrillar activity against another
amyloidogenic molecule of Ab. Thus, it is tempting to propose
that b-synuclein can have a potential to be widely applied for
controlling pathologically abnormal protein aggregations.
b-Synuclein was shown to be more eﬀective than a-synuclein
in terms of its molecular chaperone activity. Despite their se-
quence homology and structural similarity, b-synuclein lacks
the hydrophobic middle region of a-synuclein (residues 71–82)
and also the acidic C-terminal regions of a- and b-synucleins
are signiﬁcantly distinct [2,19,25]. Thus, these structural dif-
ferences in primary sequences seem to be the major reason why
the chaperone activities of the two synucleins are diﬀerent.
Since the N-terminus of a-synuclein including non-Ab com-
ponent (NAC) of AD amyloid has been suggested to serve as a
substrate binding domain for the chaperone function [16], the
lack of 11 residues of the NAC within b-synuclein might lead
to the chaperone activity of b-synuclein diﬀerent from that of
a-synuclein by improving its ability to bind and suppress ag-
gregations of denatured proteins. Furthermore, although both
synucleins have highly charged and ﬂexible regions in their C-
termini, the sequence variation in these regions might be also
responsible for the enhanced chaperone activity of b-synuclein.
Based on the previous report that the C-terminus of a-synuc-
lein is particularly important in performing the chaperone
function [16], it can be hypothesized that any diﬀerences in the
C-terminal composition of b-synuclein can increase its ability
to prevent the protein aggregation. Moreover, the C-terminus
of b-synuclein shows a certain degree of sequence homology
with the charged region found in the protein family of Hsp 90,
an abundant heat shock protein in eukaryotic cells (Fig. 4).
The charged region in the eukaryotic Hsp 90 followed by the
N-terminal chaperonic site has been reported to give Hsp 90 a
higher aﬃnity for denatured polypeptides [26], suggesting that
the C-terminus of b-synuclein might be important during the
recognition of the denatured protein.
b-Synuclein is abundantly expressed along with a-synuclein
throughout the central nervous system of normal physiology.
However, it was observed that the mRNA level of a-synuclein
was increased, while the level of b-synuclein was decreased in
the substantia nigra region of Lewy body diseases such as PD
and diﬀuse Lewy body disease [17]. The relevance of the de-
creased level of b-synuclein during the pathogenesis has not
been clariﬁed yet. However, it was reported that overexpres-
sion of a-synuclein in mice and ﬂies resulted in PD-like phe-
notypes [8,9] and double expression with b-synuclein
ameliorated the motor deﬁcit with the reduced formation of
inclusion bodies [18]. These observations suggest that changes
in the levels of both synucleins may be important for the
progress of the disease. Therefore, balance between the twoand b-synuclein. The alignment was carried out using the MultAlin
mino acids are shaded.
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could be hypothesized to play a crucial role on cellular pro-
tection [17,28]. In this point of view, functional study of b-
synuclein is needed in order to identify physiological and
pathological roles of synucleins. Since a-synuclein could be
readily damaged by environmental stresses and undergo ab-
normal protein aggregation, it is speculated that the propor-
tionally high level of b-synuclein inside the cell could
complement the deﬁciency of a-synuclein in addition to the
fact that b-synuclein can prevent the protein aggregation
through direct molecular interaction.
In conclusion, anti-aggregative activity of b-synuclein is re-
markably higher than that of a-synuclein against the heat-in-
duced aggregation of diﬀerent proteins and also b-synuclein
inhibits the amyloid formation of both Ab1–40 and a-synuclein.
It is suggested that b-synuclein can prevent abnormal protein
aggregations more eﬃciently than a-synuclein by acting as a
molecular chaperone, although it remains to be investigated
whether b-synuclein can function in the same way under nor-
mal cellular environment.
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